One-Month DAPT in CABG Patients

This study is looking at whether adding ticagrelor (a blood-thinning medication) for one month to low-dose aspirin is better than low-dose aspirin alone for people who have had coronary artery bypass grafting (CABG) surgery. CABG is a surgery to improve blood flow to the heart in people with chronic coronary disease. You could join if you are 18 or older and are having your first elective CABG with a saphenous vein graft. The study will measure if this treatment can reduce the risk of death, stroke, heart attack, repeat procedures, or graft failure over one year. The current recruitment status is unclear.

Study design: This is a multinational, randomized study planning to enroll 700 participants. It compares two treatment approaches for patients undergoing CABG surgery.
What's involved: You would take either ticagrelor 90 mg twice daily plus low-dose aspirin, or low-dose aspirin alone, for one month. You would also need to comply with all study procedures and follow-up for at least 5 years.
Compensation: Not stated in the trial record.
Follow-up: Participants will be followed for at least 5 years, with primary outcomes measured at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

One-Month DAPT in CABG Patients

Recruiting

PHASE3Ages 18+InterventionalPrevention

Weill Medical College of Cornell University

~700 participants

Updated 2025-12-22 on ClinicalTrials.gov

What's tested:Ticagrelor 90 MGLow-dose aspirin

At a glance

Recruiting sites

17 of 22 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Hierarchical composite of time to death, stroke, myocardial infarction, repeat revascularization and any graft failure.

Measured over 1 year

Conditions

Chronic Coronary Disease

Where it's being run

22 sites across 9 states

Germany7

Austria3

China3

Sweden3

New York2

New Jersey1

Innsbruck1

Ontario1

Study leadership

Marc Ruel, MD, MPH · PRINCIPAL_INVESTIGATOR · Ottawa Heart Institute Research Corporation
Mario Gaudino, MD, PhD, MSCE · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University

Who to contact

Trisha Ali-Shaw

[email protected]

646-962-8281

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Age ≥18 years

Elective first-time CABG with use of ≥1 saphenous vein graft;

Ability to sign informed consent and comply with all study procedures, including follow-up for at least 5 years.

Exclusion

Any indication for dual antiplatelet therapy, including

Acute/recent (within 1 year) ACS (NSTE-ACS or STEMI)

Recent PCI requiring continuation of dual antiplatelet therapy after CABG

Current or anticipated use of oral anticoagulation;

Paroxysmal, persistent or permanent atrial fibrillation;

Any concomitant cardiac or non-cardiac procedure;

Planned cardiac or non-cardiac surgery within one year;

Preoperative end-organ dysfunction (dialysis, moderate to severe liver failure, respiratory failure), cancer or other non-cardiac comorbidity with a life expectancy \<5 years;

Inability to use the saphenous vein;

Contraindications to the use of aspirin;

Contraindications to the use of ticagrelor, including

Known hypersensitivity to ticagrelor

Active pathological bleeding (including, but not limited to gastrointestinal or intracranial bleeding)

History of intracranial hemorrhage

Concomitant therapy with strong CYP3A4 inhibitors (eg ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir)

Inability to undergo coronary computed tomographic angiography (CCTA);

Participating in another investigational device or drug study;

Women of childbearing potential

Any major perioperative complication including, but not limited to, stroke, TIA, MI, CABG-related bleeding (BARC type 4), sepsis.

What this trial measures

Hierarchical composite of time to death, stroke, myocardial infarction, repeat revascularization and any graft failure.1 year
This is a composite endpoint to be compared between groups in a hierarchical order using the win ratio method. The following hierarchy is pre-specified: 1. Time to all-cause mortality 2. Time to stroke 3. Time to myocardial infarction 4. Time to coronary revascularization 5. Presence of graft failure at 12-month imaging follow-up or on unscheduled imaging prior to 12 month

Trialytics